Glucagon-like peptide-1 inhalation - MannKind Corporation

Drug Profile

Glucagon-like peptide-1 inhalation - MannKind Corporation

Alternative Names: GLP-1/Technosphere®; MKC 253; MKC253 Inhalation Powder

Latest Information Update: 21 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MannKind Corporation
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2011 Discontinued - Phase-I for Type-2 diabetes mellitus in Netherlands (Inhalation)
  • 02 Oct 2009 Efficacy data from a phase I trial in Type-2 diabetes mellitus, comparing the effects of MKC 253 with exenatide presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD-2009)
  • 09 Jun 2009 Pharmacodynamics and pharmacokinetics data from phase I trials in Healthy volunteers and Type-2 diabetes mellitus presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA-2009) ,,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top